Chen Schor

When we spend our days developing transformative therapies to defeat cancer, it’s important to take a moment to connect with our colleagues and enjoy the journey! Friendly competition & lots of fun at our Summer party! #Adicetlife #greatplacetowork #celltherapy #biotechnology

As our pipeline progresses, we expanded into a new state-of-the-art facility! We look forward to calling this home as we live our mission to deliver best-in-class gamma delta T cell therapies for patients fighting cancer! #Adicetlife #greatplacetowork #celltherapy #biotechnology

Presence of gamma-delta1 T cells is strongly associated with survival of patients with Non-Small Cell Lung Cancer and several additional solid tumors. Check recent nature cancer publication June 2022.

@AdicetBio announces positive clinical data for ADI-001 at #ASCO22. #celltherapy #CART #biotechnology investor.adicetbio.com/news-releases/…

We are pleased to be accepted not only for an oral presentation but also discussion in one of the featured Clinical Science Symposia at #ASCO22! #celltherapy #oncology #biotechnology #CART $ACET @AdicetBio

On #WorldCancerDay, we stand in unity with the researchers, volunteers and advocates working to reimagine a world without #cancer. #CloseTheCareGap #cancersupport #celltherapy #biotechnology #TCellRx

Proud to publish preclinical characterization of the 1st clinical stage gamma delta CAR T cell therapy, ADI-001 for B cell lymphomas. Data show potent, rapid, targeted activity of innate, adaptive and CAR-mediated mechanisms. #celltherapy #CARTcell #biotechnology @ClinTransImmuno

Leading the next breakthroughs in cell therapy, @AdicetBio CSO, @blake_aftab, discusses the promise of innate, adaptive and CAR mechanisms in our allogeneic gamma delta CAR T cell platform at the Multifunctional Cell Therapies Summit! @CAR_TCell #celltherapy #biotechnology

Happy to share our first publication for ADI-002, @Adicet Bio’s investigational #gammadelta #CAR T #celltherapy for solid tumors targeting GPC-3 – Check it out! @JIT @SITCancer jitc.bmj.com/content/9/12/e…

Excellent outcome for Adicet! #celltherapy #gammadelta #biotechnology #financing investor.adicetbio.com/news-releases/…

We are extremely proud of the interim data we announced today in B-cell Non-Hodgkin’s Lymphoma – and we’re just getting started! #celltherapy #gammadelta #biotechnology #cancer #pioneers investor.adicetbio.com/news-releases/…